-
![SUBSTITUTED PYRAZOLO[3,4-b]PYRIDIN-6-CARBOXYLIC ACIDS AND METHOD OF USE](data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='200' height='200' viewBox='0 0 200 200'%3E%3Crect width='100%25' height='100%25' fill='%23eee'%3E%3C/rect%3E%3Ctext x='50%25' y='50%25' dominant-baseline='middle' text-anchor='middle' fill='%23333333' font-family='Helvetica' font-size='20' font-weight='bold'%3ENo Pic%3C/text%3E%3C/svg%3E)
公开(公告)号：US20170101406A1
公开(公告)日：2017-04-13
申请号：US15287922
申请日：2016-10-07
Applicant: AbbVie S.à.r.l. , Galapagos NV
Inventor： Rhalid Akkari , Luke Jonathan Alvey , Xavier Marie Bock , Pieter Isabelle Roger Claes , Marlon D. Cowart , Elsa De Lemos , Nicolas Desroy , Béranger Duthion , Gregory A. Gfesser , Romain Luc Marie Gosmini , Christopher Gaëtan Housseman , Koen Karel Jansen , Jianguo Ji , Philip R. Kym , Jean-Michel Lefrancois , Oscar Mammoliti , Christel Jeanne Marie Menet , Gregory John Robert Newsome , Adeline Marie Elise Palisse , Sachin V Patel , Mathieu Rafaël Pizzonero , Anurupa Shrestha , Elizabeth C. Swift , Steven Emiel Van der Plas , Xueqing Wang
IPC: C07D471/04 , A61K31/5377 , C07D519/00 , A61K31/496 , A61K31/541 , A61K31/506 , A61K45/06 , A61K31/437
CPC classification number: C07D471/04 , A61K31/437 , A61K31/444 , A61K31/4545 , A61K31/496 , A61K31/506 , A61K31/5377 , A61K31/541 , A61K45/06 , C07D519/00 , A61K2300/00
Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R3, and R4 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).
![SUBSTITUTED PYRAZOLO[3,4-b]PYRIDIN-6-CARBOXYLIC ACIDS AND METHOD OF USE](/docs/US/2017-04-13/US20170101406A1/abs.jpg.600x600.jpg)
-
公开(公告)号：US10647717B2
公开(公告)日：2020-05-12
申请号：US16444495
申请日：2019-06-18
Applicant: AbbVie S.à.r.l. , Galapagos NV
Inventor： Rhalid Akkari , Luke Jonathan Alvey , Xavier Marie Bock , Brian S. Brown , Pieter Isabelle Roger Claes , Marlon D. Cowart , Elsa De Lemos , Nicolas Desroy , Béranger Duthion , Gregory A. Gfesser , Romain Luc Marie Gosmini , Christopher Gaëtan Housseman , Koen Karel Jansen , Jianguo Ji , Philip R. Kym , Jean-Michel Lefrancois , Oscar Mammoliti , Christel Jeanne Marie Menet , Nuria Merayo Merayo , Gregory John Robert Newsome , Adeline Marie Elise Palisse , Sachin V. Patel , Matthieu Rafaël Pizzonero , Anurupa Shrestha , Elizabeth C. Swift , Steven Emiel Van der Plas , Xueqing Wang , Ann de Blieck
IPC: C07D471/04 , A61K31/437 , C07D519/00 , A61K31/4545 , A61K31/506 , A61K31/5377 , A61K45/06
Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R3, R4, R5, and R6 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).
![N-sulfonylated-pyrazolo[3,4-b]pyridin-6-carboxamides and method of use](/docs/US/2020-05-12/US10647717B2/abs.jpg.600x600.jpg)
-
公开(公告)号：US20190202823A1
公开(公告)日：2019-07-04
申请号：US16293973
申请日：2019-03-06
Applicant: AbbVie S.à.r.l. , Galapagos NV
Inventor： Rhalid Akkari , Luke Jonathan Alvey , Xavier Marie Bock , Brian S. Brown , Pieter Isabelle Roger Claes , Marlon D. Cowart , Elsa De Lemos , Nicolas Desroy , Béranger Duthion , Gregory A. Gfesser , Romain Luc Marie Gosmini , Christopher Gaëtan Housseman , Koen Karel Jansen , Jianguo Ji , Philip R. Kym , Jean-Michel Lefrancois , Oscar Mammoliti , Christel Jeanne Marie Menet , Nuria Merayo Merayo , Gregory John Robert Newsome , Adeline Marie Elise Palisse , Sachin V. Patel , Matthieu Rafaël Pizzonero , Anurupa Shrestha , Elizabeth C. Swift , Steven Emiel Van der Plas , Xueqing Wang , Ann de Blieck
IPC: C07D471/04 , A61K45/06 , A61K31/5377 , A61K31/4545 , C07D519/00 , A61K31/437 , A61K31/506
CPC classification number: C07D471/04 , A61K31/437 , A61K31/4545 , A61K31/506 , A61K31/5377 , A61K45/06 , C07D519/00 , A61K2300/00
Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R3, R4, R5, and R6 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).
![N-SULFONYLATED PYRAZOLO[3,4-b]PYRIDIN-6-CARBOXAMIDES AND METHOD OF USE](/docs/US/2019-07-04/US20190202823A1/abs.jpg.600x600.jpg)
-
公开(公告)号：US10259810B2
公开(公告)日：2019-04-16
申请号：US15843917
申请日：2017-12-15
Applicant: AbbVie S.à.r.l. , Galapagos NV
Inventor： Rhalid Akkari , Luke Jonathan Alvey , Xavier Marie Bock , Brian S. Brown , Pieter Isabelle Roger Claes , Marlon D. Cowart , Elsa De Lemos , Nicolas Desroy , Béranger Duthion , Gregory A. Gfesser , Romain Luc Marie Gosmini , Christopher Gaëtan Housseman , Koen Karel Jansen , Jianguo Ji , Philip R. Kym , Jean-Michel Lefrancois , Oscar Mammoliti , Christel Jeanne Marie Menet , Nuria Merayo Merayo , Gregory John Robert Newsome , Adeline Marie Elise Palisse , Sachin V. Patel , Matthieu Rafaël Pizzonero , Anurupa Shrestha , Elizabeth C. Swift , Steven Emiel Van der Plas , Xueqing Wang , Ann de Blieck
IPC: C07D471/04 , A61K45/06 , A61K31/506 , A61K31/4545 , A61K31/5377 , A61K31/437 , C07D519/00
Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R3, R4, R5, and R6 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).
![N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use](/docs/US/2019-04-16/US10259810B2/abs.jpg.600x600.jpg)
-
公开(公告)号：US10130622B2
公开(公告)日：2018-11-20
申请号：US15288400
申请日：2016-10-07
Applicant: AbbVie S.à.r.l. , Galapagos NV
Inventor： Rhalid Akkari , Luke Jonathan Alvey , Xavier Marie Bock , Brian S. Brown , Pieter Isabelle Roger Claes , Marlon D. Cowart , Katja E. Conrath , Douglas Cyr , Elsa De Lemos , Gert Jules Hector De Wilde , Nicolas Desroy , Béranger Duthion , Gregory A. Gfesser , Romain Luc Marie Gosmini , Christopher Gaëtan Housseman , Koen Karel Jansen , Jianguo Ji , Philip R. Kym , Jean-Michel Lefrancois , Oscar Mammoliti , Christel Jeanne Marie Menet , Nuria Merayo Merayo , Gregory John Robert Newsome , Adeline Marie Elise Palisse , Sachin V. Patel , Mathieu Rafaël Pizzonero , Anurupa Shrestha , Elizabeth C. Swift , Chris Tse , Steven Emiel Van der Plas , Xueqing Wang
IPC: A61K31/437 , A61K31/4545 , C07D471/04 , C07D519/00 , A61K45/06 , G01N33/50
Abstract: A corrector agent capable of stabilizing a newly synthesized cystic fibrosis transmembrane conductance regulator (CFTR) protein, useful in the treatment of cystic fibrosis.
-
公开(公告)号：US20170101405A1
公开(公告)日：2017-04-13
申请号：US15287911
申请日：2016-10-07
Applicant: AbbVie S.à.r.l , Galapagos NV
Inventor： Rhalid Akkari , Luke Jonathan Alvey , Xavier Marie Bock , Brian S. Brown , Pieter Isabelle Roger Claes , Marlon D. Cowart , Elsa De Lemos , Nicolas Desroy , Béranger Duthion , Gregory A. Gfesser , Romain Luc Marie Gosmini , Christopher Gaëtan Housseman , Koen Karel Jansen , Jianguo Ji , Philip R. Kym , Jean-Michel Lefrancois , Oscar Mammoliti , Christel Jeanne Marie Menet , Nuria Merayo Merayo , Gregory John Robert Newsome , Adeline Marie Elise Palisse , Sachin V. Patel , Matthieu Rafaël Pizzonero , Anurupa Shrestha , Elizabeth C. Swift , Steven Em iel Van der Plas , Xueqing Wang , Ann de Blieck
IPC: C07D471/04 , A61K31/4545 , A61K31/437 , A61K31/506 , A61K45/06 , A61K31/5377
CPC classification number: C07D471/04 , A61K31/437 , A61K31/4545 , A61K31/506 , A61K31/5377 , A61K45/06 , C07D519/00 , A61K2300/00
Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R3, R4, R5, and R6 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).
![N-SULFONYLATED PYRAZOLO[3,4-b]PYRIDIN-6-CARBOXAMIDES AND METHOD OF USE](/docs/US/2017-04-13/US20170101405A1/abs.jpg.600x600.jpg)
-
公开(公告)号：US20190330207A1
公开(公告)日：2019-10-31
申请号：US16444495
申请日：2019-06-18
Applicant: AbbVie S.à.r.l. , Galapagos NV
Inventor： Rhalid Akkari , Luke Jonathan Alvey , Xavier Marie Bock , Brian S. Brown , Pieter Isabelle Roger Claes , Marlon D. Cowart , Elsa De Lemos , Nicolas Desroy , Béranger Duthion , Gregory A. Gfesser , Romain Luc Marie Gosmini , Christopher Gaëtan Housseman , Koen Karel Jansen , Jianguo Ji , Philip R. Kym , Jean-Michel Lefrancois , Oscar Mammoliti , Christel Jeanne Marie Menet , Nuria Merayo Merayo , Gregory John Robert Newsome , Adeline Marie Elise Palisse , Sachin V. Patel , Matthieu Rafaël Pizzonero , Anurupa Shrestha , Elizabeth C. Swift , Steven Emiel Van der Plas , Xueqing Wang , Ann de Blieck
IPC: C07D471/04 , A61K45/06 , A61K31/5377 , A61K31/4545 , C07D519/00 , A61K31/437 , A61K31/506
Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R3, R4, R5, and R6 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).
![N-Sulfonylated-Pyrazolo[3,4-b]Pyridin-6-Carboxamides and Method of Use](/docs/US/2019-10-31/US20190330207A1/abs.jpg.600x600.jpg)
-
公开(公告)号：US20180105522A1
公开(公告)日：2018-04-19
申请号：US15843917
申请日：2017-12-15
Applicant: AbbVie S.à.r.l. , Galapagos NV
Inventor： Rhalid Akkari , Luke Jonathan Alvey , Xavier Marie Bock , Brian S. Brown , Pieter Isabelle Roger Claes , Marlon D. Cowart , Elsa De Lemos , Nicolas Desroy , Béranger Duthion , Gregory A. Gfesser , Romain Luc Marie Gosmini , Christopher Gaëtan Housseman , Koen Karel Jansen , Jianguo Ji , Philip R. Kym , Jean-Michel Lefrancois , Oscar Mammoliti , Christel Jeanne Marie Menet , Nuria Merayo Merayo , Gregory John Robert Newsome , Adeline Marie Elise Palisse , Sachin V. Patel , Matthieu Rafaël Pizzonero , Anurupa Shrestha , Elizabeth C. Swift , Steven Emiel Van der Plas , Xueqing Wang , Ann de Blieck
IPC: C07D471/04 , A61K45/06 , A61K31/437 , C07D519/00 , A61K31/506 , A61K31/5377 , A61K31/4545
CPC classification number: C07D471/04 , A61K31/437 , A61K31/4545 , A61K31/506 , A61K31/5377 , A61K45/06 , C07D519/00 , A61K2300/00
Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R3, R4, R5, and R6 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).
![N-SULFONYLATED PYRAZOLO[3,4-b]PYRIDIN-6-CARBOXAMIDES AND METHOD OF USE](/docs/US/2018-04-19/US20180105522A1/abs.jpg.600x600.jpg)
-
公开(公告)号：US09890158B2
公开(公告)日：2018-02-13
申请号：US15287911
申请日：2016-10-07
Applicant: AbbVie S.à.r.l , Galapagos NV
Inventor： Rhalid Akkari , Luke Jonathan Alvey , Xavier Marie Bock , Brian S. Brown , Pieter Isabelle Roger Claes , Marlon D. Cowart , Elsa De Lemos , Nicolas Desroy , Béranger Duthion , Gregory A. Gfesser , Romain Luc Marie Gosmini , Christopher Gaëtan Housseman , Koen Karel Jansen , Jianguo Ji , Philip R. Kym , Jean-Michel Lefrancois , Oscar Mammoliti , Christel Jeanne Marie Menet , Nuria Merayo Merayo , Gregory John Robert Newsome , Adeline Marie Elise Palisse , Sachin V. Patel , Matthieu Rafaël Pizzonero , Anurupa Shrestha , Elizabeth C. Swift , Steven Emiel Van der Plas , Xueqing Wang , Ann de Blieck
IPC: C07D471/04 , A61K45/06 , A61K31/506 , A61K31/5377 , A61K31/4545 , A61K31/437 , C07D519/00
CPC classification number: C07D471/04 , A61K31/437 , A61K31/4545 , A61K31/506 , A61K31/5377 , A61K45/06 , C07D519/00 , A61K2300/00
Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R3, R4, R5, and R6 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).
![N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use](/docs/US/2018-02-13/US09890158B2/abs.jpg.600x600.jpg)
-
公开(公告)号：US20170100386A1
公开(公告)日：2017-04-13
申请号：US15288400
申请日：2016-10-07
Applicant: AbbVie S.à.r.l. , Galapagos NV
Inventor： Rhalid Akkari , Luke Jonathan Alvey , Xavier Marie Bock , Brian S. Brown , Pieter Isabelle Roger Claes , Marlon D. Cowart , Katja E. Conrath , Douglas Cyr , Elsa De Lemos , Gert Jules Hector De Wilde , Nicolas Desroy , Béranger Duthion , Gregory A. Gfesser , Romain Luc Marie Gosmini , Christopher Gaëtan Housseman , Koen Karel Jansen , Jianguo Ji , Philip R. Kym , Jean-Michel Lefrancois , Oscar Mammoliti , Christel Jeanne Marie Menet , Nuria Merayo Merayo , Gregory John Robert Newsome , Adeline Marie Elise Palisse , Sachin V. Patel , Mathieu Rafaël Pizzonero , Anurupa Shrestha , Elizabeth C. Swift , Chris Tse , Steven Emiel Van der Plas , Xueqing Wang
IPC: A61K31/4545 , G01N33/50 , A61K45/06
CPC classification number: A61K31/4545 , A61K45/06 , C07D471/04 , C07D519/00 , G01N33/5023 , G01N2800/382
Abstract: A corrector agent capable of stabilizing a newly synthesized cystic fibrosis transmembrane conductance regulator (CFTR) protein, useful in the treatment of cystic fibrosis.
